Search bioRxiv⌕ Search

bioRxiv · 10.1101/034215

Ewing sarcoma breakpoint region 1 prevents transcription-associated genome instability

Abstract

Ewing Sarcoma break point region 1 (EWSR1) is a multi-functional RNA-binding protein that is involved in many cellular processes, from gene expression to RNA processing and transport. Translocations into its locus lead to chimeric proteins with tumorigenic activity, that lack the RNA binding domain. With crosslinking and immunoprecipitation we have found that EWSR1 binds to intronic regions that are present in polyadenylated nuclear RNAs, which include the translocation-prone region of its own locus. Reduced EWSR1 expression leads to gene expression changes that indicate reduced proliferation. By fluorescence in situ hybridization (FISH) with break-apart probes that flanked the translocation-prone region within the EWSR1 locus we found that reduced EWSR1 expression increases the frequency of split signals, indicative of DNA double strand breaks (DSB). The response in phosphorylated histone H2AX and p53-binding protein 1 (53BP1) double-stained foci to the topoisomerase poison camptothecin in cells treated with a control shRNA and with sh-EWSR1 further suggests that EWSR1 functions in the prevention of DNA DSBs. Our data reveal a new function of the EWSR1 member of the FET family and suggest a connection between the RNA-binding activity of EWSR1 and the instability of its own locus that may play a role in malignancy-associated translocations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nitish Mittal, Christophe Kunz, Foivos Gypas, Shivendra Kishore, Georges Martin, Friedel Wenzel, Erik van Nimwegen, Primo Schaer, Mihaela Zavolan. 2015-12-15. Ewing sarcoma breakpoint region 1 prevents transcription-associated genome instability. https://doi.org/10.1101/034215

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Personalized Immunotherapy via Multiscale Tumor-Immune Modeling and Optimal Control

Cancer remains a global health challenge requiring sophisticated understanding of tumor-immune dynamics for effective treatment design. Mathematical oncology has emerged as a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. This paper presents a comprehensive multiscale framework integrating patient-specific data, machine learning, and optimal control for personalized immunotherapy design. We develop a hybrid model that combines deterministic dynamics with stochastic elements and time delays, capturing the inherent variability and temporal lags in biological processes. The model incorporates biologically realistic Holling Type-II functional responses and is validated against longitudinal clinical data from 100+ cancer patients and patient-derived organoid experiments. Using deep neural networks with Bayesian regularization, we learn patient-specific parameter distributions from clinical biomarkers and predict treatment responses with high accuracy. Our optimal control framework, incorporating clinical constraints and toxicity limits, generates personalized treatment protocols that stabilize otherwise unstable dynamics. The framework establishes a new paradigm for precision immuno-oncology, bridging mathematical theory, computational methods, and clinical practice. Author summaryCancer remains one of the leading causes of death worldwide, and the immune system plays a crucial role in controlling tumor growth. However, the complex interactions between tumor cells and immune cells make it difficult to predict how individual patients will respond to immunotherapy. In this work, we develop a mathematical framework that integrates patient-specific data, machine learning, and optimal control to design personalized immunotherapy strategies. Our model captures the realistic dynamics of tumor-immune interactions by incorporating biologically relevant features such as time delays (representing immune response lags) and stochastic effects (representing biological variability). Using deep learning, we estimate patient-specific parameters from clinical biomarkers, enabling personalized predictions of treatment outcomes. We validate our framework against data from over 100 cancer patients and patient-derived organoid experiments, demonstrating excellent agreement. Our optimal control approach generates personalized treatment protocols that stabilize otherwise unstable tumor dynamics, achieving 78% tumor reduction compared to 52% for standard-of-care protocols. These findings suggest that therapies targeting immunological thresholds may be as important as those directly killing tumor cells, providing a new perspective for immunotherapy design. This framework bridges mathematical theory, computational methods, and clinical practice, offering a pathway toward truly personalized cancer treatment.

Systems Biology↗

Reversible Opto-Chemical activation of KRASG12V signaling with near single-cell precision

KRAS mutations drive some of the most lethal carcinomas, and genomic and inducible systems have established many of the cellular and tissue-level consequences. However, these approaches operate at the level of oncogene expression, allowing for cellular adaptation that masks the individual role of KRAS oncoprotein signaling. Here, we developed a reversible Opto-Chemical system to activate KRAS signaling by chemically translocating a cytosolic mutant KRASG12V G-domain to the plasma membrane upon light or small-molecule input. In MDCK cells, the G-domain plasma membrane recruitment activated downstream signaling and reduced collective migration. In mouse small Intestinal Organoids, G-domain recruitment promoted increased crypt size and number under Epidermal Growth Factor-deprived conditions. We further showed that the increased number of crypts depended on continuous KRASG12V signaling. Finally, under the same deprived conditions, localized activation in just one budding crypt promoted crypt formation compared to controls. This system decouples oncoprotein activity from oncogene expression, allowing to investigate the KRAS signaling contribution to early epithelial transformation.

Systems Biology↗

Mammalian aging involves genome-wide splicing degeneration leading to functional decline

Alternative splicing exhibits significant changes during development and aging, affecting the composition and variance in the transcriptome. However, it is unclear whether and how age-associated splicing dysregulation leads to functional consequences. Here, an integrative analysis of transcriptome data across mouse and human tissues revealed that aging is characterized by systematic deterioration of the fidelity of RNA splicing, here termed splicing degeneration, a measure of functional alteration of reading frame and domain configuration of protein products. Genes with higher aging-associated splicing degeneration were more conserved and enriched for processes such as RNA metabolism and antigen presentation. By assessing alternative splicing events associated with functional deterioration, we quantified the degree of splicing degeneration. Its level increased with age but was alleviated following calorie restriction or rapamycin treatment, indicating that it can serve as a new molecular hallmark of aging. Mechanistically, through a comprehensive meta-data analysis, we discovered that splicing degeneration is associated with age-associated changes in specific splicing factors, which in turn showed a strong association with age-related transcriptome changes. Overall, our study demonstrates the intricate relationship between aging and genome-wide splicing degeneration, revealing a promising target for aging interventions acting to reverse splicing degeneration.

Systems Biology↗